Metabolic Disorders
89bio wins EMA priority status for MASH candidate pegozafermin
The European Medicine’s Agency (EMA) has granted priority medicines (PRIME) status to 89bio’s pegozafermin, a drug being evaluated to treat…
Viking reports positive data from Phase I oral obesity treatment trial
Viking Therapeutics has reported positive data from its Phase I multiple ascending dose (MAD) clinical trial of VK2735, an oral…
Hua Medicine plans to focus T2D drug on diabetic kidney disease patients
China-based Hua Medicine plans to focus on the US trial development of its type 2 diabetes (T2D) drug in diabetic…
Pipeline moves: Approval prospects for SBS candidate rise after Phase III trial meets endpoints
This week on Pipeline Moves, we kick off by looking at success of a Phase III trial of Ironwood Pharmaceuticals’…
Empros Pharma to dose patients in Phase III obesity trial before end of year
Swedish biopharma Empros Pharma will dose the first subjects with its obesity combination therapy in a Phase III trial before…
89bio kicks off Phase III trial for pegozafermin in MASH
89bio has initiated its Phase III trial ENLIGHTEN-Fibrosis evaluating pegozafermin in patients with non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) patients with…
Regor Therapeutics begins Phase II trial of obesity treatment
Regor Therapeutics has commenced a Phase II clinical trial for its oral glucagon-like peptide-1 (GLP-1) agonist, RGT-075, designed for adults…
Insulet touts results from Omnipod 5 trial in type 1 diabetes patients
US-based Insulet has unveiled positive results from a study investigating its Omnipod 5 system compared to insulin pump therapy with…
GLP1-RAs linked with reduced risk of depression, study claims
A study claims that there is a link between weight-loss drugs and a reduced risk of depression and anxiety. The…
Viking triumphs with positive Phase II results for weight loss drug
Viking Therapeutics has released topline results from the Phase II trial of its dual agonist of the glucagon-like peptide 1…